Lack of over-expression of T cell receptor Vbeta5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls

G Afshar; P A Muraro; H F McFarland; R Martin

doi:10.1016/s0165-5728(97)00215-4

Lack of over-expression of T cell receptor Vbeta5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls

J Neuroimmunol. 1998 Apr 1;84(1):7-13. doi: 10.1016/s0165-5728(97)00215-4.

Authors

G Afshar¹, P A Muraro, H F McFarland, R Martin

Affiliation

¹ Neuroimmunology Branch, NINDS, National Institutes of Health, Bethesda, MD 20892-1400, USA.

PMID: 9600703
DOI: 10.1016/s0165-5728(97)00215-4

Abstract

Based on studies reporting an overexpression of certain V genes in myelin basic protein (MBP)-specific T cells from MS patients, immunotherapies targeting single TCR (Vbeta5.2, Vbeta6.1) are currently under way. In order to assess the basic assumption for one of these therapeutic strategies, i.e. the overexpression of Vbeta5.2 by MBP-specific T cells, we analyzed 100 MBP-specific T cell lines (TCL) for Vbeta5.2 expression. Only 4 out of 100 TCL expressed Vbeta5.2, and expression of this TCR gene is therefore not more frequent than expected from the normal peripheral blood distribution.

MeSH terms

Adult
Aged
Female
Genes, T-Cell Receptor beta / genetics*
HLA-DR2 Antigen / immunology
Humans
Immunotherapy
Leukocytes, Mononuclear / immunology
Male
Middle Aged
Multiple Sclerosis / genetics
Multiple Sclerosis / immunology*
Multiple Sclerosis / metabolism
Myelin Basic Protein / metabolism
RNA, Messenger / metabolism*
T-Lymphocytes / immunology
T-Lymphocytes / metabolism*

Substances

HLA-DR2 Antigen
Myelin Basic Protein
RNA, Messenger